Skip to main content
. 2020 Jul;9(7):4111–4120. doi: 10.21037/tcr-20-1451

Table 4. Clinical response according to LMR-week 6 for melanoma patients.

Response Number (N=40, %) Low LMR-week 6 (N=17, 42.5%) High LMR-week 6 (N=23, 57.5%)
CR 2 (5.0) 0 (0.0) 2 (8.7)
PR 1 (2.5) 0 (0.0) 1 (4.3)
SD 16 (40.0) 9 (52.9) 7 (30.5)
PD 21 (52.5) 8 (47.1) 13 (56.5)

N, number; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; LMR-week 6, lymphocyte-to-monocyte ratio 6 weeks after the start of PD-1 inhibitors.